MARKER THERAPEUTICS, INC. Retained Earnings
MARKER THERAPEUTICS, INC. (MRKR) had Retained Earnings of -$464.19 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$464.19M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$462.36M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$459.18M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$457.48M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$464.19M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$462.36M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | -$459.18M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | -$457.48M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$455.48M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$451.46M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$447.02M 10-K · filed 2026-03-18 | |
| 2024-09-30 | -$443.18M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$440.87M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$438.68M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$436.29M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$433.48M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$430.50M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$433.02M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$428.05M 10-K · filed 2024-03-26 | |
| 2022-09-30 | -$424.19M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$417.27M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$408.03M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | -$398.12M 10-K · filed 2023-03-22 | |
| 2021-09-30 | -$388.36M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$375.93M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | -$365.02M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | -$356.24M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$347.73M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | -$340.36M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | -$334.02M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | -$327.53M 10-K · filed 2021-03-09 | |
| 2019-09-30 | -$322.45M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | -$316.99M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | -$311.42M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | -$306.11M 10-K · filed 2020-03-12 | |
| 2018-09-30 | -$170.55M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | -$166.16M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | -$160.62M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | -$157.42M 10-K · filed 2019-03-15 | |
| 2017-09-30 | -$154.74M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | -$150.75M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | -$148.24M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | -$145.82M 10-K · filed 2018-03-23 | |
| 2016-09-30 | -$144.24M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | -$132.28M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | -$138.26M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | -$133.51M 10-K · filed 2017-03-14 | |
| 2015-09-30 | -$131.86M 10-Q/A · filed 2016-04-14 | -$103.25M 10-Q · filed 2015-11-16 |
| 2015-06-30 | -$160.36M 10-Q/A · filed 2016-04-14 | -$105.74M 10-Q · filed 2015-08-14 |
| 2015-03-31 | -$94.01M 10-Q/A · filed 2016-04-14 | |
| 2014-12-31 | -$86.31M 10-Q/A · filed 2016-04-14 | |
| 2014-09-30 | -$55.57K 10-Q · filed 2014-11-19 | |
| 2013-12-31 | -$55.43M 10-K · filed 2015-04-15 | -$58.33K 10-Q · filed 2014-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |